High approval probability already priced at 86%. Hunter syndrome rare disease indication favorable, but no cash available to trade.

Royalty Pharma's $275M approval-contingent deal and NEJM data validate the 86% odds. With PDUFA on April 5, selling reallocates capital to multiple March catalysts, maximizing portfolio velocity. Steady-state cap reduced request to $1000.00.

Addresses a critical unmet need by treating neurological symptoms of Hunter syndrome. Strong data published in a major journal and prior approval in Japan suggest a higher probability of approval than the market price... Steady-state cap reduced request to $1000.00.

Rare disease Hunter Syndrome has high unmet need, supporting >86% approval odds. Approval drives major RPRX valuation upside via royalty stream. Steady-state cap reduced request to $1000.00.

Ph1/2 shows big CSF/urine heparan sulfate drops, but frequent infusion reactions keep some CRL risk; at 86% YES looks fair and RPRX impact likely modest (royalty upside vs $200m payout).